Biocryst Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BIOCRYST
BIOCRYST has three approved drugs.
There are eighteen US patents protecting BIOCRYST drugs.
There are one hundred and twenty-eight patent family members on BIOCRYST drugs in forty countries and seventeen supplementary protection certificates in fifteen countries.
Summary for Biocryst
| International Patents: | 128 |
| US Patents: | 18 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 3 |
Drugs and US Patents for Biocryst
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biocryst | ORLADEYO | berotralstat dihydrochloride | CAPSULE;ORAL | 214094-001 | Dec 3, 2020 | RX | Yes | No | 11,230,530*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Biocryst | ORLADEYO | berotralstat dihydrochloride | PELLETS;ORAL | 219776-002 | Dec 11, 2025 | RX | Yes | No | 10,329,260*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Biocryst | ORLADEYO | berotralstat dihydrochloride | CAPSULE;ORAL | 214094-001 | Dec 3, 2020 | RX | Yes | No | 10,662,160*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Biocryst | ORLADEYO | berotralstat dihydrochloride | PELLETS;ORAL | 219776-004 | Dec 11, 2025 | RX | Yes | Yes | 10,689,346*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Biocryst
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | 6,503,745 | ⤷ Start Trial |
| Biocryst | RAPIVAB | peramivir | SOLUTION;INTRAVENOUS | 206426-001 | Dec 19, 2014 | 6,562,861 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Biocryst Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| France | 21C1048 | ⤷ Start Trial |
| Canada | 3164693 | ⤷ Start Trial |
| Lithuania | C3113772 | ⤷ Start Trial |
| Mexico | 2020002008 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Biocryst Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3113772 | C03113772/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: BEROTRALSTAT; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68464 07.06.2022 |
| 3113772 | SPC/GB21/061 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: BEROTRALSTAT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/21/1544(FOR NI) 20210504; UK FURTHER MA ON IPSUM 20210504 |
| 3113772 | C202130056 | Spain | ⤷ Start Trial | PRODUCT NAME: BEROTRALSTAT Y SALES FARMACEUTICAMENTE ACEPTABLES DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/21/1544; DATE OF AUTHORISATION: 20210430; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1544; DATE OF FIRST AUTHORISATION IN EEA: 20210430 |
| 3113772 | 122021000062 | Germany | ⤷ Start Trial | PRODUCT NAME: BEROTRALSTAT ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1544 20210430 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
